Literature DB >> 17726832

Treatment Options for HIV-Associated Tuberculosis.

Philip Chukwuka Onyebujoh1, Isabela Ribeiro, Christopher Curtis Whalen.   

Abstract

The vicious interaction between the human immunodeficiency virus (HIV) infection and tuberculosis (TB) pandemics poses special challenges to national control programs and individual physicians. Although recommendations for the treatment of TB in HIV-infected patients do not significantly differ from those for HIV-uninfected patients, the appropriate management of HIV-associated TB is complicated by health system issues, diagnostic difficulties, adherence concerns, overlapping adverse-effect profiles and drug interactions, and the occurrence of paradoxical reactions after the initiation of effective antiretroviral therapy. In this article, recommended treatment strategies and novel approaches to the management of HIV-associated TB are reviewed, including adjuvant treatment and options for treatment simplification. A focused research agenda is proposed in the context of the limitations of the current knowledge framework.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17726832      PMCID: PMC2860284          DOI: 10.1086/518657

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  69 in total

1.  The action of antituberculosis drugs in short-course chemotherapy.

Authors:  D A Mitchison
Journal:  Tubercle       Date:  1985-09

2.  Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.

Authors:  A Vernon; W Burman; D Benator; A Khan; L Bozeman
Journal:  Lancet       Date:  1999-05-29       Impact factor: 79.321

3.  Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months.

Authors: 
Journal:  Tubercle       Date:  1981-06

Review 4.  The clinical pharmacokinetics of rifabutin.

Authors:  T F Blaschke; M H Skinner
Journal:  Clin Infect Dis       Date:  1996-04       Impact factor: 9.079

5.  Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial.

Authors:  S Z Wiktor; M Sassan-Morokro; A D Grant; L Abouya; J M Karon; C Maurice; G Djomand; A Ackah; K Domoua; A Kadio; A Yapi; P Combe; O Tossou; T H Roels; E M Lackritz; D Coulibaly; K M De Cock; I M Coulibaly; A E Greenberg
Journal:  Lancet       Date:  1999-05-01       Impact factor: 79.321

6.  Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Durban Immunotherapy Trial Group.

Authors: 
Journal:  Lancet       Date:  1999-07-10       Impact factor: 79.321

7.  Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study.

Authors: 
Journal:  Tubercle       Date:  1986-03

8.  Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial.

Authors:  R S Wallis; P Nsubuga; C Whalen; R D Mugerwa; A Okwera; D Oette; J B Jackson; J L Johnson; J J Ellner
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

9.  In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Authors:  B Ji; N Lounis; C Maslo; C Truffot-Pernot; P Bonnafous; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

Review 10.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272

View more
  16 in total

1.  Experience with rifabutin replacing rifampin in the treatment of tuberculosis.

Authors:  D J Horne; C Spitters; M Narita
Journal:  Int J Tuberc Lung Dis       Date:  2011-11       Impact factor: 2.373

2.  Validating five questions of antiretroviral nonadherence in a public-sector treatment program in rural South Africa.

Authors:  Krisda Chaiyachati; Lisa R Hirschhorn; Frank Tanser; Marie-Louise Newell; Till Bärnighausen
Journal:  AIDS Patient Care STDS       Date:  2011-01-26       Impact factor: 5.078

3.  The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis.

Authors:  E J Ragan; M B Kleinman; B Sweigart; N Gnatienko; C D Parry; C R Horsburgh; M P LaValley; B Myers; K R Jacobson
Journal:  Int J Tuberc Lung Dis       Date:  2020-01-01       Impact factor: 2.373

Review 4.  Initiating antiretrovirals during tuberculosis treatment: a drug safety review.

Authors:  Tanuja N Gengiah; Andrew L Gray; Kogieleum Naidoo; Quarraisha Abdool Karim
Journal:  Expert Opin Drug Saf       Date:  2011-01-05       Impact factor: 4.250

Review 5.  Tuberculosis and HIV co-infection: screening and treatment strategies.

Authors:  Kartik K Venkatesh; Soumya Swaminathan; Jason R Andrews; Kenneth H Mayer
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

6.  Synthesis of deoxygenated alpha(1-->5)-linked arabinofuranose disaccharides as substrates and inhibitors of arabinosyltransferases of Mycobacterium tuberculosis.

Authors:  Ashish K Pathak; Vibha Pathak; William J Suling; James R Riordan; Sudagar S Gurcha; Gurdyal S Besra; Robert C Reynolds
Journal:  Bioorg Med Chem       Date:  2008-11-18       Impact factor: 3.641

7.  Genital tuberculosis as the cause of tuboovarian abscess in an immunosuppressed patient.

Authors:  M Ilmer; F Bergauer; K Friese; I Mylonas
Journal:  Infect Dis Obstet Gynecol       Date:  2010-03-08

Review 8.  Extensively drug-resistant tuberculosis: a new face to an old pathogen.

Authors:  Sheela Shenoi; Gerald Friedland
Journal:  Annu Rev Med       Date:  2009       Impact factor: 13.739

Review 9.  Tuberculous pleural effusion.

Authors:  José M Porcel
Journal:  Lung       Date:  2009-08-13       Impact factor: 2.584

10.  Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV.

Authors:  Payam Tabarsi; Ali S Saber-Tehrani; Parvaneh Baghaei; Mojgan Padyab; Davood Mansouri; Majid Amiri; Mohammad Reza Masjedi; Frederick L Altice
Journal:  J Int AIDS Soc       Date:  2009-07-16       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.